Last reviewed · How we verify

placebo plus paclitaxel — Competitive Intelligence Brief

placebo plus paclitaxel (placebo plus paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane. Area: Oncology.

phase 3 Taxane Microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

placebo plus paclitaxel (placebo plus paclitaxel) — Biotech Pharmaceutical Co., Ltd.. Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from growing and spreading.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
placebo plus paclitaxel TARGET placebo plus paclitaxel Biotech Pharmaceutical Co., Ltd. phase 3 Taxane Microtubules
Ivermectin + colchicine Ivermectin + colchicine Ain Shams University marketed Antiparasitic + anti-inflammatory combination Glutamate-gated chloride channels (ivermectin); tubulin/microtubules (colchicine)
Paclitaxel (Pac) Paclitaxel (Pac) Aravive, Inc. marketed Taxane; microtubule stabilizer β-tubulin / microtubules
Paclitaxel, Carboplatin Paclitaxel, Carboplatin Queensland Centre for Gynaecological Cancer marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (carboplatin)
docetaxel and cisplatin docetaxel and cisplatin Sanofi marketed Chemotherapy combination (taxane + platinum agent) Microtubules (docetaxel); DNA (cisplatin)
Dose dense AC followed by T + trastuzumab Dose dense AC followed by T + trastuzumab Agendia marketed Chemotherapy regimen with monoclonal antibody HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
nab-paclitaxel，Cisplatin nab-paclitaxel，Cisplatin Yang Jianjun, PhD marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane class)

  1. Sanofi · 3 drugs in this class
  2. Akeso · 1 drug in this class
  3. Fourth Affiliated Hospital of Guangxi Medical University · 1 drug in this class
  4. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
  5. Central European Society for Anticancer Drug Research · 1 drug in this class
  6. Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class
  7. Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
  8. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Jina Pharmaceuticals Inc. · 1 drug in this class
  10. Air Force Military Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). placebo plus paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-plus-paclitaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: